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p57 (Kip2, cyclin-dependent kinase inhibitor 1C), often found downregulated in cancer, is reported to hold tumor suppressor
properties. Originally described as a cyclin-dependent kinase (cdk) inhibitor, p57
KIP2 has since been shown to inﬂuence other
cellular processes, beyond cell cycle regulation, including cell death and cell migration. Inhibition of cell migration by p57
KIP2 is
attributed to the stabilization of the actin cytoskeleton through the activation of LIM domain kinase-1 (LIMK-1). Furthermore,
p57
KIP2 is able to enhance mitochondrial-mediated apoptosis. Here, we report that the cell death promoting effect of p57
KIP2 is
linked to its effect on the actin cytoskeleton. Indeed, whereas Jasplakinolide, an actin cytoskeleton-stabilizing agent, mimicked
p57
KIP2’s pro-apoptotic effect, destabilizing the actin cytoskeleton with cytochalsin D reversed p57
KIP2’s pro-apoptotic function.
Conversely, LIMK-1, the enzyme mediating p57
KIP2’s effect on the actincytoskeleton, was requiredfor p57
KIP2’s death promoting
effect. Finally, p57
KIP2-mediated stabilization of the actin cytoskeleton was associated with the displacement of hexokinase-1, an
inhibitor of the mitochondrial voltage-dependent anion channel, from the mitochondria, providing a possible mechanism for the
promotion of the mitochondrial apoptotic cell death pathway. Altogether, our ﬁndings link together two tumor suppressor
propertiesofp57
KIP2,byshowingthatthepromotionofcelldeathbyp57
KIP2requiresitsactincytoskeletonstabilizationfunction.
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p57 (Kip2, cyclin-dependent kinase inhibitor 1C) has been
described as a potential tumor suppressor gene due to its
ability to inhibit several of the hallmarks of cancer.
1 The
importance of p57
KIP2 in the suppression of cancer is
highlighted by its mutation/inactivation in Beckwith-Wiede-
mann Syndrome, a cancer pre-disposing syndrome,
2 and its
reported decrease in protein expression in cancers of the
breast, lung, liver, and prostate, among others.
3–8 Inhibition
of p57
KIP2 expression in cancer cells is mediated by
promoter DNA methylation at CpG islands and/or by histone
modiﬁcations, such as methylation and deacetylation.
1
Worth a notice, the lack of p57
KIP2 expression in tumors is
associated with poor survival, and has been identiﬁed as
prognostic marker for many of the aforementioned cancer
types.
1
Initially identiﬁed as a member of the Cip/Kip family of Cdk
(cyclin-dependent kinase) inhibitors,
9,10 p57
KIP2 has since
beenshowntohavediversecellularrolesasidefrom cellcycle
inhibition, for example, promotion of cell death,
11–13 inhibition
of cell migration,
14 and regulation of cell differentiation.
15–17
Indeed, considering that p57
KIP2 null mice have increased
embryonic lethality and gross developmental defects as
compared with p21
CIP1/CDKN1A and p27
KIP2/CDKN1B null mice,
it appears that the cellular roles of p57
KIP2 surpass that of the
other Cdk inhibitors.
18–20
The ease at which cancer cells migrate and invade a
neighboring tissue demonstrates the importance of regulators
of cell cytoskeleton structure in the cancer progression. The
cytoskeleton remodeling factor coﬁlin disassembles actin
ﬁlaments and thereby facilitates cell migration through increas-
ing the actin mobile fraction.
21 Active unphosphorylated coﬁlin is
associated with increased tumor metastasis.
22 Coﬁlin can be
inactivated by LIM domain kinase-1/2 (LIMK-1/2),
23,24 which are
themselves activated by phosphorylation on Thr508
25 through
the Rho/Rho kinase (ROCK) signaling pathway.
26 Interestingly,
p57
KIP2 interacts with LIM domain kinase-1 (LIMK-1) and
increases its kinase activity independently of Rho/ROCK
signaling and thereby contributes to the stabilization of actin
ﬁlaments and the inhibition of cell migration.
14
p57
KIP2 expression can enhance cell death induced by
staurosporine (STS) and DNA damaging agents such as
etoposide and cisplatin, all of which induce apoptotic
mitochondrial events.
11,12 In contrast, p57
KIP2 has no poten-
tiating effect on apoptosis induced by death receptor ligand,
12
indicating that p57
KIP2 enhances cell death speciﬁcally at the
level of the mitochondria. Indeed, overexpression of Bcl-2 or
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nel (VDAC) inhibited p57
KIP2’s cell death promoting effect.
12
Interestingly, there are reports that actin can inﬂuence the
conductance of VDAC channels. In Neurospora crassa,a n
abundance of monomeric actin facilitated the closure of VDAC
channels, whereas stable ﬁlamentous actin (F-actin) was
unable to do the same.
27 In fact, the presence of F-actin led to
an increased ion conductance across the outer mitochondrial
membrane. This indicated a possible link between the stability
of actin cytoskeleton and the integrity of the mitochondrial
transmembrane potential. In this study, we investigated the
possibility that the cell death promoting effect of p57
KIP2
requires its actin cytoskeleton-stabilizing effect.
Results
p57
KIP2 stabilizes the actin cytoskeleton and promotes
apoptosis. Two of the tumor suppressor characteristics of
p57
KIP2 include inhibition of cell migration and promotion of
apoptosis.
11,12,14 In this study, we took advantage of HeLa
Tet-On derived cell line stably transfected with tetracycline-
inducible p57
KIP2, HeLa-p57
KIP2 cells. These cells can be
induced to express p57
KIP2 selectively, upon administration
of the tetracycline analog doxycycline (Dox) (Figure 1a).
Induction of p57
KIP2 expression in HeLa-p57
KIP2 cells led to
an increased formation of actin stress ﬁbers as visualized by
staining with phalloidin, which binds F-actin (Figure 1b).
Additionally, ﬂuorescence recovery after photobleaching
(FRAP) analysis of green ﬂuorescence protein (GFP)-labe-
led-actin revealed a reduced actin-GFP mobile fraction in
HeLa-p57
KIP2 cells treated with Dox as compared with
untreated cells, providing additional evidence for the actin
cytoskeleton-stabilizing function of p57
KIP2 (Figure 1c).
Although, induction of p57
KIP2 expression did not provoke
cell death per se, it sensitized cells to apoptosis triggered by
STS (Figures 1d and e, Supplementary Figure S1).
It has already been established that stabilization of the actin
cytoskeleton can induce apoptotic cell death.
28,29 Jasplakino-
lide(Jasp),anactincytoskeleton-stabilizingagent,wasusedto
investigate whether actin cytoskeleton stabilization increases
cell death induced by STS, thereby mimicking the effect of
p57
KIP2.
30 At the concentration used in this study, Jasp
stabilized the actin cytoskeleton, as shown by FRAP measure-
ment of the mobility of actin-GFP (Figure 1c), but did
not increase cell death (Figures 1d and e, Supplementary
Figure S1). Pre-treatment of HeLa-p57
KIP2 cells with Jasp
30min before STS treatment resulted in an increase in cells
exhibiting apoptotic nuclear morphology (Figure 1d,
Supplementary Figure S1) and poly ADP-ribose polymerase
(PARP)cleavage(Figure1e),similartolevelsobservedincells
co-treated with Dox and STS. Importantly, induction of p57
KIP2
expression by Dox treatment did not signiﬁcantly increase the
celldeathcausedbyJaspandSTSco-treatmentindicatingthat
indeed Jasp mimics the pro-apoptotic effect of p57
KIP2.
Destabilization of actin ﬁlaments inhibits p57
KIP2
enhancement of STS-induced cell death. As actin cyto-
skeleton stabilization mimicked the pro-apoptotic effects of
p57
KIP2, an actin cytoskeleton destabilizing agent
cytochalasin D (Cyto. D),
31 was used to investigate whether
depolymerization of actin ﬁlaments could prevent the
promotion of cell death by p57
KIP2. Cyto. D was used at a
concentration that does not induce cell death, but yet retains
the ability to destabilize the actin cytoskeleton (Figures 2a–c).
FRAP analysis of actin-GFP mobility in HeLa-p57 cells
treated with Dox showed that treatment with Cyto. D for 3h
successfully reversed the actin cytoskeleton-stabilizing effect
of p57
KIP2 (Figure 2a). To assess the effect of actin
depolymerization on the p57
KIP2-death promoting effect,
HeLa-p57
KIP2 cells were treated with Dox and STS with or
without Cyto. D pre-treatment. Cells co-treated with Dox and
STS presented reduced apoptotic nuclear morphology in the
presence of Cyto. D (Figure 2b: 7.2% with Cyto. D versus
22.2% without Cyto. D). Furthermore, the increase in cleaved
PARP in HeLa-p57
KIP2 cells treated with STS was reduced in
the presence of Cyto. D (Figure 2c). Therefore, one could
conclude that actin cytoskeleton destabilization inhibits the
ability of p57
KIP2 to enhance STS-induced apoptotic cell
death.
LIMK-1 is required for p57
KIP2-induced cell death. Acti-
vation of LIMK-1 kinase results in decreased coﬁlin activity
through phosphorylation and as such, increased actin
cytoskeleton stabilization.
26 It has previously been shown
that p57
KIP2 directly interacts with LIMK-1 resulting in an
increase in LIMK-1 kinase activity, which is required for
p57
KIP2-mediated actin cytoskeleton stabilization.
14 To inves-
tigate whether LIMK-1 is required for p57
KIP2-mediated
apoptosis, small interfering RNA (siRNA) directed against
LIMK-1 were used, which resulted in the speciﬁc knockdown
of LIMK-1 protein levels (Figure 3a).
In HeLa-p57
KIP2 cells co-treated with Dox and STS, there
was a reduction in the apoptotic nuclei to 6.7% in LIMK-1
knockdown cells as compared with 15.2% in LIMK-1 expres-
sing cells (Figure 3b). In fact, the number of apoptotic nuclei in
LIMK-1 knockdown cells co-treated with Dox and STS were
similar to those observed in cells treated only with STS
(Figure 3b). Similarly, measurement of DEVDase activity also
showed a decrease caspase-3 like activity in cells co-treated
with Dox and STS when LIMK-1 expression was suppressed
as compared with the control (Figure 3c). Furthermore,
analysis of PARP cleavage by immunoblot conﬁrmed that in
LIMK-1 deﬁcient cells, p57
KIP2 was unable to enhance STS-
mediated cleavage of this caspase-3 substrate (Figure 3d).
Together,theseresultsdemonstratedthatsilencingofLIMK-1
prevented p57
KIP2 enhancement of STS-induced apoptosis.
Thus, this additionally established that loss of the actin-
stabilizing effect of p57
KIP2 is sufﬁcient to prevent its pro-
apoptotic effect.
Actin cytoskeleton stabilization by p57
KIP2 positively
modulates apoptosis at the mitochondrial level. So far, it
has been established that the pro-apoptotic effect of p57
KIP2
requires its ability to stabilize the actin cytoskeleton. This
death promoting effect of p57
KIP2 was previously shown to be
mediated through the mitochondria.
12 Indeed treatment of
HeLa-p57
KIP2 cells with Dox and STS increased the loss of
mitochondrial transmembrane potential (DCm) compared
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Cell Death and DiseaseFigure 1 Cytoskeleton stabilization enhances STS-induced apoptosis. (a) HeLa-p57 TET-on cells were treated with Dox for 24h. p57
KIP2 expression was analyzed by
immunoblotting, and (b) actin ﬁlaments were stained with phalloiden. (c) The mobile actin fraction following exposure to Dox or Jasp (3h) was measured by FRAP analysis of
cells transfected with actin-GFP. Values represent the % ﬂuorescence recovery over time of actin-GFP after bleaching. Arrows indicate the photobleached area. (d) HeLa-
p57
KIP2 cells were treated with Jasp for 30min, followed by treatment with STS for 3h with or without exposure to Dox. Apoptotic nuclear morphology was quantiﬁed after
Hoechststainingandexpressedasthepercentageofthetotalcellscounted.(e)PARPcleavagewasassessedbyimmunoblotting.G3PDHwasusedasaloadingcontrol.Full
length (f) and cleaved (c) PARP was analyzed by densitometry and cleaved PARP was expressed as a % of total PARP (%c)
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Cell Death and Diseasewith STS treatment alone (Figure 4a). The importance of
actin dynamic for maintenance of DCm is demonstrated by
the ability of Jasp to enhance STS-induced loss in DCm
(Figure 4b), and of Cyto. D to reduce the loss of DCm
induced by Dox and STS co-treatment (Figure 4c). Further-
more, in the presence of a kinase-inactive mutant of LIMK-1
(LIMK-1-D460A), p57
KIP2 expression did not enhance STS-
induced loss of DCm (Figure 4d). In all, these results show
that a stable actin cytoskeleton, induced by p57
KIP2,
positively modulates apoptosis at the mitochondrial level.
Actin stabilization by p57
KIP2 displaces hexokinase-1
(HK-1) from mitochondria. Previous work has shown
that inhibition of VDAC channel opening using 4,4’-diisothio-
cyanatostilbene-2,2’-disulfonic acid (DIDS) counteracts the
p57
KIP2-death promoting effect.
14 Therefore, the effect of
p57
KIP2 on the mitochondrial protein levels of HK-1, an
important regulator of VDAC channel conductance, was
examined. A decrease in mitochondrial localization
of HK-1 was observed upon Dox treatment of HeLa-
p57
KIP2 cells (Figure 5a), Actin cytoskeleton stabilization
by Jasp also resulted in a decrease in mitochondrial HK-1
(Figure 5a). Finally, the ability of HK-1 to rescue cells from
apoptosis induced by p57
KIP2 was investigated. Accord-
ingly, overexpression of HK-1 in p57
KIP2 expressing cells
resulted in a decrease in cleaved caspase-3 staining
compared with the pcDNA-transfected control (Figures 4b
and c).
Figure2 Cytoskeletondestabilizationpreventstheenhancementofapoptosisbyp57
KIP2.(a)FRAPanalysisofHeLa-p57
KIP2cellstreatedwithorwithoutcytochalsinDfor
3h. Values representthe % ﬂuorescence recoveryover timeof actin-GFPafter bleaching. Arrows indicate thephotobleached area. (b and c) HeLa-p57
KIP2 cells were treated
withcytochalsinDfor1h,followedbytreatmentwithSTSfor3h.(b)ApoptoticnuclearmorphologywasquantiﬁedafterHoechststainingandexpressedasapercentageofthe
total cells counted. (c) PARP cleavage was assessed by immunoblotting. G3PDH was used as a loading control. Full length (f) and cleaved (c) PARP was analyzed by
densitometry and cleaved PARP was expressed as a % of total PARP (%c)
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Cell Death and DiseaseDiscussion
p57
KIP2 inhibits many of the hallmarks of cancer and as such
has been hailed as a potential tumor suppressor gene.
1 The
resultsinthisstudycorroborate previousstudiesshowing ﬁrstly
that p57
KIP2 inhibits cancer cell migration through stabilization
of the actin cytoskeleton, and secondly that p57
KIP2 enhances
apoptotic cancer cell death through mitochondrial depolariza-
tion. This study examines the interplay between these two
seemingly disparate functions of p57
KIP2,a n ds h o w st h a tt h e
pro-apoptotic effect of p57
KIP2 depends on its ability to stabilize
the actin cytoskeleton. Disturbing actin cytoskeleton dynamics
affects the ability of p57
KIP2 to promote cell death. We here
show that stabilizing the actin cytoskeleton mimics the death
promoting effect of p57
KIP2, and destabilizing actin ﬁlaments
reverses this effect. Signiﬁcantly, inhibition of the actin
cytoskeleton-stabilizing effect of p57
KIP2 (through LIMK-1
knockdown) also abrogates the death promoting effect of
p57
KIP2, providing a direct link between the actin cytoskeleton-
stabilizing function of p57
KIP2 and the death promoting function
of p57
KIP2. Stabilization of actin cytoskeleton has been shown
to induce cell death.
28,32 Although to date, the mechanism by
which F-actin sensitizes to cell death is not fully described,
evidence suggests that it is through mitochondrial depolariza-
tion.
27,32 Further investigation into how p57
KIP2 sensitizes cells
todeathrevealedalinkbetweenactincytoskeletonstabilization
and mitochondrial hexokinase levels. Hexokinase is often
found overexpressed in cancer cells, where its binding to
mitochondria enhances the cell’s rate of glycolysis through
easyaccessto mitochondrial-generated ATP.
33 The closure of
Figure 3 LIMK-1 is required for p57
KIP2-induced apoptosis. HeLa-p57
KIP2
cells were transfected with scrambled sequence siRNA or LIMK-1 siRNA in the
presence or absence of Dox (24h) and STS (3h). (a) LIMK-1 knockdown was
conﬁrmed by immunoblotting against LIMK-1, using G3PDH as a loading control.
(b) Apoptotic nuclear morphology was quantiﬁed by Hoechst staining and
expressed as a percentage of the total cells counted. (c) Activation of effector
caspases was measuredbyDEVDaseassay,expressedasfold increaseof control.
Values represent the mean þ/  S.D. of three separate experiments. (d) PARP
cleavage was assessed by immunoblotting, using G3PDH as a protein loading
control. Full length (f) and cleaved (c) PARP was analyzed by densitometry and
cleaved PARP was expressed as a % of total PARP (%c)
Figure 4 Actin cytoskeleton stabilization by p57
KIP2 promotes DCm. HeLa-p57
KIP2 cells were treated STS in the presence or absence of Dox. (a)T h e
DCm was measured by ﬂow cytometry after staining with TMRE. (b) HeLa-p57
KIP2 cells were treated with Jasp for 30min, followed by treatment with STS for 5h.
The DCm was measured by ﬂow cytometry after staining with TMRE. (c) HeLa-p57
KIP2 cells were treated with Cytochalsin D for 30min, followed by treatment with STS
for 3h in the presence of Dox. The DCm was measured by ﬂow cytometry after staining with TMRE. (d) HeLa-p57
KIP2 cells were transfected with wild-type LIMK
(LIMK-WT) or a kinase-inactive mutant of LIMK (LIMK-D460A) before treatment with Dox and STS. The DCm was measured by ﬂow cytometry after staining
with TMRE
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Cell Death and DiseaseVDAC channels upon hexokinase binding is one mechanism
used by cancer cells to evade death.
34 This study shows that
actin cytoskeleton stabilization either by Jasp or by p57
KIP2
expression displaces HK-1 from the mitochondrial membrane.
In fact, overexpression of HK-1 inhibits the promotion of cell
death by p57
KIP2. This describes a scenario whereby stabiliza-
tion of actin by p57
KIP2 promotes cell death through the
displacementofHK-1fromthemitochondria.Manycancercells
exhibit decreased p57
KIP2 expression either through promoter
DNA methylation, histone modiﬁcations, genetic mutation,
silencing by microRNA’s, or proteasomal degradation.
1 Inter-
estingly, induced p57
KIP2 expression in tumors forces regres-
sion of the cancer.
35 Therefore, as with many tumor
suppressors, it is important for the cancer to keep expression
of p57
KIP2 at a reduced level. Consequently, p57
KIP2 protein
expression is being tested as a prognostic indicator in cancer.
In this study, we have shown that the negative regulation of at
leasttwocancerhallmarks,increasedcellmigration-metastasis
and evasion of cell death, can be traced back to the ability of
p57
KIP2 to stabilize actin cytoskeleton. Potentially, other hall-
marks of cancer could also be regulated by p57
KIP2 regulation
of the actin cytoskeleton dynamic. Already, increased actin
mobility is known to enhance tumor angiogenesis.
36 These
ﬁndings should increase interest in therapies that reactivate
p57
KIP2 expression in cancer cells.
Materials and Methods
Plasmids and siRNA. Myc-LIMK-1 and Myc-LIMK-1 D640A mutant in the
FPC1 vector were gifts from K Mizuno (Tohoku University, Japan). Actin-GFP
plasmid was a gift from Pirta Hotulainen (University of Helsinki, Finland). GFP
plasmid was from Clontech (Invitrogen, Carlsbad, CA, USA). SMARTPool siRNA
against LIMK-1 and non-targeted sequence were purchased from Dharmacon
(Lafayette, CO, USA).
Cell culture, transfections, and treatments. Human cervical
carcinoma HeLa cells expressing p57
KIP2 under the control of the tetracycline
promoter (HeLa-p57
KIP2) were a gift from S Okret, Karolinska Institutet and were
cultured in MEM medium (Gibco, Carlsbad, CA, USA) supplemented with
10% Fetal bovine serum, penicillin/streptomycin, non-essential amino acids,
sodium pyruvate, and L-glutamine. 2mg/ml Dox was added to the culture medium
for 24h to induce expression of p57
KIP2. Transfections were performed with
Lipofectamine and Plus reagent (Invitrogen) according to the manufacturer’s
protocol. Cells were treated with 0.1mM Jasp, 1mM Cytochalsin D, or 0.1mM STS
for the indicated times.
Protein extracts and immunoblotting. Cells were harvested and lysed
by sonication in NP40 lysis buffer containing protease inhibitors.
17 Protein lysates
were heated to 951C for 5min in Laemmli buffer. In all, 20–40mg proteins were
electrophoresed on 12% SDS-PAGE acrylamide gels, and then immunoblotted
onto nitrocellulose membrane. Membranes were blocked in 5% milk and incubated
with anti-PARP (BD Pharmingen, Franklin Lakes, NJ, USA), anti-p57
KIP2 (C-20,
Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-HK-1 (N-19, Santa Cruz
Biotechnology), anti-GFP (Santa Cruz Biotechnology), anti-translocase of outer
membrane 40 (tom40; Santa Cruz Biotechnology), or anti-glycerol 3 phosphate
dehydrogenase (G3PDH; Trevigen, Gaithersburg, MD, USA) overnight at 41C,
followed by incubation with the appropriate horseradish peroxidase secondary
antibody (1:10000) for 1h at room temperature. Bands were visualized by
enhanced chemiluminescence (Pierce, Rockford, IL, USA) following the
manufacturers protocol.
Fluorescence recovery after photobleaching (FRAP). FRAP was
used to assess the amount of mobile actin-GFP monomers. HeLa- p57
KIP2 cells,
grown on glass chamber slides, were transfected with actin-GFP and treated as
indicated in the ﬁgure legends. Chamber slides were then placed in the POC-
chamber/CTI Controller/heating insert P system for live cell imaging. After
bleaching the region of interest (ROI) with 100% intensity of Argon/2 laser 488nm
(current 4.7Amp), the time course of ﬂuorescence recovery in the bleached ROI
was monitored with 20ms intervals. Samples were analyzed with Axiovert 200m
microscope (Zeiss, Oberkochen, Germany).
Measurement of effector caspase-3/7 (DEVDase) activity. DEV-
Dase activity in cell lysates was calculated by measuring the rate of cleavage of
the ﬂuorogenic DEVD-MCA substrate (Peptide Institute Inc., Osaka, Japan). Free
AMC was monitored in a Fluoroscan II plate reader (Labsystems, Waltham, MA,
USA) using 355 nm excitation and 460 nm emission wavelengths.
Measurement of mitochondrial transmembrane potential. Cells
were incubated with 25nM tetramethylrhodamine ethyl ester (TMRE) (Molecular
Probes, Carlsbad, CA, USA) at 371C for 30min before harvesting. Cells were
washed twice in phosphate-buffered saline (PBS), trypsinised, resuspended in
PBS and analyzed by ﬂow cytometry on a FACSCalibur (Becton Dickinson,
Franklin Lakes, NJ, USA) ﬂow cytometer. Results were analyzed using CellQuest
(Becton Dickinson) software.
Subcellular fractionation. Harvested cells were washed twice in PBS and
resuspended for 10min on ice in buffer A (10mM Hepes, pH 7.9 at 41C, 1.5mM
MgCl2, 10mM KCl and 0.5mM DTT). Cells were centrifuged at 2000r.p.m. for
5min at 41C. Cell pellet was resuspended in buffer A containing 0.2% NP40 and
protease inhibitors for 2min on ice. Cells were centrifuged at 500r.p.m. for 2min.
The supernatant was collected and further centrifuged at 14000r.p.m. for 30min.
The supernatant and pellet contained the cytosolic and mitochondrial fractions,
respectively.
Quantiﬁcation of apoptotic nuclear morphology. Cells were
grown on glass coverslips, treated, and ﬁxed with 4% paraformaldehyde
for 15min at 41C. Fixed cells were then incubated in Hoechst (1mg/ml)
for 10min at room temperature to stain nuclei. At least 200 cells were counted per
sample.
Figure 5 Actin stabilization by p57KIP2 promotes displacement of HK-1 from
mitochondria. (a) HeLa-p57
KIP2 cells were treated with either Dox or Jasp.
Mitochondrial and cytosolic protein fractions were analyzed by immunoblotting using
antibodies against HK-1. Tom40 was used as a mitochondrial loading control.
Asterisk (*
) indicates a cleavage product of HK-1. Values represent the fold
decrease of full-length HK-1 compared with control. (b) HeLa-p57
KIP2 cells were
transfectedwithHK-1-GFPorpcDNAandgrowninthepresenceorabsenceofDox
for 24h. Overexpression of HK-1-GFP was analyzed by immunoblotting with GFP,
using Tom40 as a loading control, and (c) cleaved caspase-3 staining was
assessed by ﬂow cytometry
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Cell Death and DiseaseDetection of F-actin. To visualize F-actin, cells grown on glass coverslips
were ﬁxed and incubated with rhodamine-conjugated phalloidin (1:8000) for
30min at room temperature. Nuclei were stained by incubating coverslips in 1mg/ml
Hoechst (Molecular Probes) for 10min at room temperature. Cells were visualized
using a 510 Meta confocal microscope (Zeiss).
Measurement of cleaved caspase-3. Cells were ﬁxed with 4%
paraformaldehyde for 10min at 371C and permeabilized with 90% methanol for
30min at  201C. Cells were incubated in blocking solution (0.5% BSA in PBS)
for 10min at room temperature, followed by anti-cleaved caspase-3 (Cell
signaling, Danvers, MA, USA; 1:3200 in blocking solution) for 1h at room
temperature, and then with goat anti-rabbit Alexa 488 (Invitrogen; 1:200 in
blocking solution) for 30min. Cells were washed once in blocking solution between
all antibody incubations, and were ﬁnally resuspended in PBS for analysis on a
FACSCalibur (Becton Dickinson) ﬂow cytometer. Results were analyzed using
CellQuest software.
Statistical analysis. Statistical analyses were performed using two tailed,
paired student’s t-test where *Po0.05 and **Po0.01 were considered to be
signiﬁcant. Bars and error bars represent mean with S.E.M.
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